Courtney Phillips, General Counsel and Corporate Secretary of Maze Therapeutics, Inc., filed a statement of changes in beneficial ownership on September 3, 2026, reporting a restricted stock unit settlement transaction dated September 1, 2026.
Key Highlights
- Reporting person: Courtney Phillips, identified as General Counsel and Corporate Secretary of Maze Therapeutics, Inc.
- Transaction date: September 1, 2026, with the filing submitted on September 3, 2026.
- RSU settlement: 11,000 restricted stock units converted to 11,000 shares of Common Stock at a price of $0 per unit, via transaction code M.
- Resulting ownership: Phillips holds 11,000 shares of Common Stock directly following the reported transaction.
- Vesting schedule: According to the filing, the award vests as to 1/2 of the total on September 1, 2026, and 1/2 on September 1, 2027, subject to continued service.
- RSU terms: The filing states these restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
Phillips RSU Settlement Details at Maze Therapeutics
According to the filing, Courtney Phillips, serving as General Counsel and Corporate Secretary at Maze Therapeutics, Inc. (NASDAQ:MAZE), reported the settlement of restricted stock units on September 1, 2026. The transaction, coded M in the filing, involved 11,000 restricted stock units that were acquired and simultaneously settled into 11,000 shares of Common Stock at a price of $0. Maze Therapeutics is a biopharmaceutical company focused on precision medicine, and Phillips, in her role as an officer, is subject to Section 16(a) reporting requirements under the Securities Exchange Act of 1934.
The filing discloses that each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock upon settlement. The award was structured to vest in two equal installments: one-half on September 1, 2026, and the remaining one-half on September 1, 2027, in each case subject to Phillips's continued service to the issuer on the applicable vesting date. The filing further notes that the restricted stock units do not carry an expiration date, and instead either vest according to schedule or are cancelled before the vesting date. Following the reported transaction, Phillips directly beneficially owns 11,000 shares of Common Stock, and 11,000 restricted stock units remain outstanding as derivative securities held directly.
What Was Disclosed
The filing reports a single transaction in which Courtney Phillips, General Counsel and Corporate Secretary of Maze Therapeutics, received 11,000 shares of Common Stock upon the settlement of an equal number of restricted stock units on September 1, 2026, at a stated price of $0.





Please wait processing your request...